Cost-effectiveness of Lecanemab for the Treatment of Early Alzheimer’s Disease: A Canadian Societal Perspective (S23.001)
To estimate the cost-effectiveness of lecanemab versus standard of care (SoC) in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD), with confirmed beta-amyloid (Aβ) pathology, from a Canadian societal perspective.
Authors
- Kevin Molloy (ORCID: https://orcid.org/0000-0002-7747-5712)
- David Trueman (ORCID: https://orcid.org/0000-0002-7886-6467)
- Kimberly Castellano
- Se Ryeong Jang
- Simon Rothwell (ORCID: https://orcid.org/0000-0003-2123-9902)
- Erin Wong (ORCID: https://orcid.org/0000-0001-5798-3472)
- Carolyn Bodnar
- Oliver Burn
- Laura Pastor (ORCID: https://orcid.org/0000-0002-5657-8464)
- Adam Haynes
Institutions
- Primary Source (US)
- EVERSANA (Canada) (CA)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212013
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13